Sihuan Pharmaceutical (HKG:0460) said its subsidiary Xuanzhu Biopharmaceutical (HKG:2575) granted exclusive commercialization rights for Bireociclib Tablets in Thailand to Innobic (Asia) and ZaoAn International, according to a Thursday filing on Hong Kong exchange.
Innobic (Asia) will handle local registration, marketing and distribution, while Xuanzhu Biopharmaceutical will supply the drug. ZaoAn International will act as intermediary and be primarily responsible for payments under purchase orders. The agreement runs through June 30, 2036.
The agreement includes annual minimum purchase requirements and license fees payable upon signing and upon obtaining Thai marketing approval.